PBMs under fire for drug prices defend their worth

Listen to the article 9 min This audio is auto-generated. Please let us know if you have feedback. The pharmacy benefit management system is complicated. Just ask Shelly Sanchez of Elixir, a PBM owned by the Rite Aid Corporation. Elixir vice president of strategic solutions Shelley Sanchez Permission granted by Elizir/Shelly Sanchez “PBMs started really … Read more

Ultra-sensitive tests bring biomarkers into the drug development forefront

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Revolutionary drugs often get the bulk of attention surrounding medical advances. But their success in the real world is intrinsically tied to the screening process that finds which patients would benefit. Quanterix CEO Masoud Toloue Permission granted … Read more

Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims

An experimental drug has enabled people with obesity or who are overweight to lose about 22.5 percent of their body weight, about 52 pounds on average, in a large trial, the drug’s maker announced on Thursday. The company, Eli Lilly, has not yet submitted the data for publication in a peer-reviewed medical journal or presented … Read more

How an open platform can shake up the drug development process

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Drug developers face substantial risks during the R&D process, and these are exacerbated when working with complex modalities and therapeutics. The nature of the process, particularly when developing therapeutics for smaller populations, as with rare diseases, also … Read more

Real-world data is making drug development more true to life

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Real-world data (RWD) has long played a supporting role in the pharma industry, primarily acting as a monitor for post-approval drug safety. Now, drugmakers are looking to save time and money using the data in new, more … Read more

Potential Policy Changes that Could Upend Prescription Drug Pricing

On November 3, 2021, Congress introduced a working draft of the Build Back Better (BBB) ​​Act. This legislation includes proposals that could drive some of the most material changes in drug pricing in the history of the Medicare Parts B and D programs. The changes are sweeping, with potential for some—such as inflation rebates—to be … Read more

Medical regulator faces questions over board members’ links to drug firms | NHS

The UK medicines watchdog has been urged to strengthen its conflict of interest policy after it emerged that six of its board members are receiving payments from the pharmaceutical industry. Board members involved in overseeing the regulator’s “strategic direction” also have financial interests in companies including US and Saudi drug giants and firms with ambitions … Read more